Transplacental treatment of fetal tachycardia: Implications of drug transporting proteins in placenta
- 1 June 2001
- journal article
- review article
- Published by Elsevier in Seminars in Perinatology
- Vol. 25 (3) , 196-201
- https://doi.org/10.1053/sper.2001.24566
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.Journal of Clinical Investigation, 1995
- Homozygous disruption of the murine MDR2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver diseasePublished by Elsevier ,1993
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Clinical and pharmacologic study of fetal supraventricular tachyarrhythmiasThe Journal of Pediatrics, 1992
- Flecainide in the treatment of fetal tachycardias.Heart, 1991
- Obstetric importance, diagnosis, and management of fetal tachycardias.BMJ, 1988
- Amiodarone and digoxin for refractory fetal tachycardiaThe American Journal of Cardiology, 1987
- Non-immunologic hydrops fetalis: a review of 27 cases.Archives of Disease in Childhood, 1983
- Fetal Echocardiography for Evaluation of in Utero Congestive Heart FailureNew England Journal of Medicine, 1982
- FETAL HEART RATES AS DETERMINED BY SONAR IN EARLY PREGNANCYBJOG: An International Journal of Obstetrics and Gynaecology, 1973